Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Novartis
University of Washington
Prelude Therapeutics
M.D. Anderson Cancer Center
University of California, Irvine
Disc Medicine, Inc
Chengdu Zenitar Biomedical Technology Co., Ltd
Peking Union Medical College Hospital
Incyte Corporation
Merck Sharp & Dohme LLC
University of Southern California
Italfarmaco
Ionis Pharmaceuticals, Inc.
Hospices Civils de Lyon
M.D. Anderson Cancer Center
Massachusetts General Hospital
University of Miami
M.D. Anderson Cancer Center
Silence Therapeutics plc
Icahn School of Medicine at Mount Sinai
University Hospital, Angers
Thomas Jefferson University
Thomas Jefferson University
M.D. Anderson Cancer Center
Ohio State University Comprehensive Cancer Center
PharmaEssentia Japan K.K.
Incyte Corporation
Hangzhou GluBio Pharmaceutical Co., Ltd.
PharmaEssentia
Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc.
PharmaEssentia
PharmaEssentia
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
Barbara Ann Karmanos Cancer Institute
Roswell Park Cancer Institute
City of Hope Medical Center
RWTH Aachen University
BeBetter Med Inc
M.D. Anderson Cancer Center
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Mabwell (Shanghai) Bioscience Co., Ltd.
Italfarmaco
AbbVie
M.D. Anderson Cancer Center
University of Birmingham
PharmaEssentia Japan K.K.